JP2000515542A5 - - Google Patents

Download PDF

Info

Publication number
JP2000515542A5
JP2000515542A5 JP1998507770A JP50777098A JP2000515542A5 JP 2000515542 A5 JP2000515542 A5 JP 2000515542A5 JP 1998507770 A JP1998507770 A JP 1998507770A JP 50777098 A JP50777098 A JP 50777098A JP 2000515542 A5 JP2000515542 A5 JP 2000515542A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP1998507770A
Other languages
English (en)
Japanese (ja)
Other versions
JP2000515542A (ja
JP4416184B2 (ja
Filing date
Publication date
Priority claimed from IL11902996A external-priority patent/IL119029A0/xx
Application filed filed Critical
Publication of JP2000515542A publication Critical patent/JP2000515542A/ja
Publication of JP2000515542A5 publication Critical patent/JP2000515542A5/ja
Application granted granted Critical
Publication of JP4416184B2 publication Critical patent/JP4416184B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP50777098A 1996-08-07 1997-08-05 長期作用型薬物およびこれらを含む薬剤組成物 Expired - Lifetime JP4416184B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL119029 1996-08-06
IL11902996A IL119029A0 (en) 1996-08-07 1996-08-07 Long-acting drugs and pharamaceutical compositions comprising them
PCT/IL1997/000265 WO1998005361A2 (en) 1996-08-07 1997-08-05 Long-acting drugs and pharmaceutical compositions comprising them

Publications (3)

Publication Number Publication Date
JP2000515542A JP2000515542A (ja) 2000-11-21
JP2000515542A5 true JP2000515542A5 (enExample) 2005-04-07
JP4416184B2 JP4416184B2 (ja) 2010-02-17

Family

ID=11069166

Family Applications (1)

Application Number Title Priority Date Filing Date
JP50777098A Expired - Lifetime JP4416184B2 (ja) 1996-08-07 1997-08-05 長期作用型薬物およびこれらを含む薬剤組成物

Country Status (18)

Country Link
US (1) US6504005B1 (enExample)
EP (1) EP1019089B1 (enExample)
JP (1) JP4416184B2 (enExample)
KR (1) KR20000029806A (enExample)
CN (1) CN1227501A (enExample)
AT (1) ATE308998T1 (enExample)
AU (1) AU725468B2 (enExample)
BR (1) BR9711045A (enExample)
CA (1) CA2261835C (enExample)
CZ (1) CZ36999A3 (enExample)
DE (1) DE69734607T2 (enExample)
DK (1) DK1019089T3 (enExample)
ES (1) ES2252787T3 (enExample)
HU (1) HUP0000809A2 (enExample)
IL (3) IL119029A0 (enExample)
NO (1) NO990518L (enExample)
NZ (1) NZ333845A (enExample)
WO (1) WO1998005361A2 (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL139400A0 (en) * 2000-11-01 2001-11-25 Yeda Res & Dev Long-acting cytokine derivatives and pharmaceutical compositions comprising them
JP2004521093A (ja) * 2000-12-13 2004-07-15 イーライ・リリー・アンド・カンパニー グルカゴン様インスリン刺激性ペプチドを用いる長期治療計画
CN101785861B (zh) * 2001-10-19 2014-08-13 爱德士实验室公司 用于药理活性化合物的可控释放的可注射组合物
US6946137B2 (en) * 2001-10-19 2005-09-20 Idexx Laboratories, Inc. Methods for the controlled delivery of pharmacologically active compounds
US20030171285A1 (en) * 2001-11-20 2003-09-11 Finn Rory F. Chemically-modified human growth hormone conjugates
BE1015608A6 (fr) * 2003-07-15 2005-06-07 Messadek Jallal Traitement des arterites.
JP4033382B2 (ja) * 2002-04-08 2008-01-16 久光製薬株式会社 インスリン投与装置
WO2004064972A2 (en) * 2003-01-16 2004-08-05 Hk Pharmaceuticals, Inc. Capture compounds, collections thereof and methods for analyzing the proteome and complex compositions
EP1620118B1 (en) 2003-04-08 2014-06-18 Yeda Research And Development Co., Ltd. Reversible pegylated drugs
EP1615632B1 (fr) * 2003-04-17 2006-12-06 Jallal Messadek Formulations orales flottantes pour la liberation controlee de la betaine
JP4463814B2 (ja) 2003-08-05 2010-05-19 ノボ ノルディスク アクティーゼルスカブ 新規のインスリン誘導体
BE1016128A6 (fr) * 2004-07-22 2006-03-07 Messadek Jallal Combinaisons therapeutiques
US7282487B2 (en) * 2004-10-28 2007-10-16 Idexx Laboratories Method for treating bacterial infections in horses or pigs with tilmicosin
WO2006050581A2 (en) * 2004-11-10 2006-05-18 Jallal Messadek Betaine as agent against arthropod - or mosquito -borne diseases
ATE540690T1 (de) * 2005-04-27 2012-01-15 Jallal Messadek Insulinkombinationen
DK1969004T3 (da) 2005-12-28 2011-11-28 Novo Nordisk As Insulinsammensætninger og metode til at lave en sammensætning
EP2167032B1 (en) 2007-06-13 2019-08-07 Novo Nordisk A/S Pharmaceutical formulation comprising an insulin derivative
WO2009065193A1 (en) * 2007-11-21 2009-05-28 Jallal Messadek Treatment of aspirin resistance with betaine and/or betaine enriched molasses
KR20110004366A (ko) 2008-03-18 2011-01-13 노보 노르디스크 에이/에스 프로테아제 안정화되고, 아실화된 인슐린 유사체
CN102076331B (zh) 2008-06-26 2013-12-18 普罗林科斯有限责任公司 具有可控的药物释放速率的前药和药物-大分子轭合物
US20110166063A1 (en) * 2008-09-19 2011-07-07 Nektar Therapeutics Polymer conjugates of therapeutic peptides
EP2344200A2 (en) * 2008-09-19 2011-07-20 Nektar Therapeutics Modified therapeutics peptides, methods of their preparation and use
US9274122B2 (en) 2008-10-21 2016-03-01 Baxalta Incorporated Methods for determining active ingredients in pro-drug PEG protein conjugates with releasable PEG reagents (in vitro de-pegylation)
WO2010049488A1 (en) * 2008-10-30 2010-05-06 Novo Nordisk A/S Treating diabetes melitus using insulin injections with less than daily injection frequency
AU2010220324A1 (en) 2009-03-05 2011-09-01 Ascendis Pharma As Interferon alpha carrier prodrugs
WO2011013128A2 (en) 2009-07-31 2011-02-03 Yeda Research And Development Co. Ltd. Vectors for delivery of neurotherapeutics to the central nervous system
CN103025165B (zh) * 2010-05-05 2016-06-08 普罗林科斯有限责任公司 自大分子共轭物的控释
DK2632478T3 (da) 2010-10-27 2019-10-07 Novo Nordisk As Behandling af diabetes melitus under anvendelse af insulinindsprøjtninger indgivet med varierende indsprøjtningsintervaller
EP2490378B1 (en) 2011-02-18 2014-07-09 NTT DoCoMo, Inc. Apparatus and method for determining a control unit using feasibility requests and feasibility responses
US10166295B2 (en) 2011-06-02 2019-01-01 Opko Biologics Ltd. Pegylated OXM variants
EP2714070B1 (en) 2011-06-02 2024-03-20 OPKO Biologics Ltd. Long-acting glp-1/glucagon receptor agonists
AU2013247047A1 (en) 2012-04-11 2014-10-23 Novo Nordisk A/S Insulin formulations
CN104684576B (zh) 2012-06-04 2019-08-06 奥普科生物制品有限公司 聚乙二醇化的oxm变体
US20150111820A1 (en) 2012-07-09 2015-04-23 Novo Nordisk A/S Novel use of insulin derivatives
EP2991672A1 (en) 2013-04-30 2016-03-09 Novo Nordisk A/S Novel administration regime
BR112019011761A2 (pt) 2016-12-16 2019-11-05 Novo Nordisk As composições farmacêuticas contendo insulina
US10335464B1 (en) 2018-06-26 2019-07-02 Novo Nordisk A/S Device for titrating basal insulin
US12441776B2 (en) 2018-11-30 2025-10-14 Eirgen Pharma Ltd. Oxyntomodulin peptide analog formulations
KR20210126088A (ko) 2019-02-11 2021-10-19 옵코 바이오로직스 리미티드 지속성 glp-2 유사체
US12343383B2 (en) 2019-07-12 2025-07-01 Novo Nordisk A/S High concentration insulin formulation
CN113773398B (zh) * 2020-06-10 2023-05-23 宁波鲲鹏生物科技有限公司 一种德谷胰岛素衍生物及其应用
CN117551008B (zh) * 2023-11-10 2025-10-17 沈阳药科大学 一种去铁胺偶联物及其制备方法和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU906340D0 (en) 1986-10-13 1991-04-29 Sandoz Ag Synthesis in solid phase for producing peptonic alcohols
GB8717446D0 (en) 1987-07-23 1987-08-26 Merck Sharp & Dohme Chemical compounds
US6313094B1 (en) * 1990-12-11 2001-11-06 Japan Energy Corporation β-amino-α-hydroxycarboxylic acid derivatives and HIV protease inhibitors
JPH0687887A (ja) * 1992-08-19 1994-03-29 Upjohn Co:The ペプチドのエナミン誘導体およびそれをプロドラッグとして含有するペプチド製剤
EP0679658A4 (en) 1993-06-25 1997-06-04 Kyowa Hakko Kogyo Kk Endothelin-antagonizing peptide.
US5880131A (en) * 1993-10-20 1999-03-09 Enzon, Inc. High molecular weight polymer-based prodrugs
DE4437604A1 (de) 1994-10-21 1996-04-25 Basf Ag Konjugate aus einem Poly- oder Oligopeptid und einer niedermolekularen lipophilen Verbindung
US5955434A (en) 1995-02-09 1999-09-21 Brigham & Women's Hospital Gel-forming polypeptide derivatives
WO1996030267A2 (en) * 1995-03-30 1996-10-03 Southpac Trust International, Inc. Self-erecting container which is collapsible to be substantially flat
US5688992A (en) 1995-03-31 1997-11-18 The United States Of America As Represented By The Department Of Health And Human Services O-malonyltryrosyl compounds, O-malonyltryrosyl compound-containing peptides, and use thereof
US5846934A (en) * 1996-02-20 1998-12-08 American Cyanamid Company Pure somatostatin antagonist and methods of use thereof
US6057297A (en) * 1996-08-06 2000-05-02 Polifarma S.P.A. Inhibitor compounds of zinc-dependent metalloproteinases associated with pathological conditions, and therapeutic use thereof

Similar Documents

Publication Publication Date Title
JP2000502280A5 (enExample)
JP2000501771A5 (enExample)
JP2000501599A5 (enExample)
JP2000501018A5 (enExample)
JP2000500076A5 (enExample)
JP2000501324A5 (enExample)
JP2000500055A5 (enExample)
JP2000500026A5 (enExample)
JP2000502472A5 (enExample)
JP2000501825A5 (enExample)
JP2000501338A5 (enExample)
JP2000500874A5 (enExample)
JP2000502425A5 (enExample)
JP2000502568A5 (enExample)
JP2000501774A5 (enExample)
JP2000500912A5 (enExample)
JP2000515542A5 (enExample)
JP2000502570A5 (enExample)
JP2000501876A5 (enExample)
JP2000501744A5 (enExample)
JP2000501229A5 (enExample)
JP2000502316A5 (enExample)
JP2000500857A5 (enExample)
JP2000502714A5 (enExample)
JP2000501569A5 (enExample)